Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study

Damiano Paolicelli; Eleonora Cocco; Valentina Di Lecce; Vita Direnzo; Lucia Moiola; Roberta Lanzillo; Paola Perini; Simona Malucchi; Giovanna Borriello; Emilio Portaccio; Valentina Panetta; Giuseppe Fenu; Francesca Sangalli; Laura Cacciaguerra; Maria Trojano; the TRACER Group for the TRACER Group

doi:10.1517/17425247.2016.1158161

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study

Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra, Maria Trojano, the TRACER Group for the TRACER Group

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of ‘not missing doses’, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined ‘treatment adherents’. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Expert Opinion on Drug Delivery
DOIs	https://doi.org/10.1517/17425247.2016.1158161
Publication status	Accepted/In press - Mar 13 2016

Fingerprint

Keywords

Disease-modifying drugs
interferon beta
patient adherence
real-life setting
rebismart® injection device
relapsing-remitting multiple sclerosis

ASJC Scopus subject areas

Pharmaceutical Science

Cite this

Paolicelli, D., Cocco, E., Di Lecce, V., Direnzo, V., Moiola, L., Lanzillo, R., Perini, P., Malucchi, S., Borriello, G., Portaccio, E., Panetta, V., Fenu, G., Sangalli, F., Cacciaguerra, L., Trojano, M., & for the TRACER Group, T. TRACER. G. (Accepted/In press). Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 1-7. https://doi.org/10.1517/17425247.2016.1158161

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis : TRACER study. / Paolicelli, Damiano; Cocco, Eleonora; Di Lecce, Valentina; Direnzo, Vita; Moiola, Lucia; Lanzillo, Roberta; Perini, Paola; Malucchi, Simona; Borriello, Giovanna; Portaccio, Emilio; Panetta, Valentina; Fenu, Giuseppe; Sangalli, Francesca; Cacciaguerra, Laura; Trojano, Maria; for the TRACER Group, the TRACER Group.

In: Expert Opinion on Drug Delivery, 13.03.2016, p. 1-7.

Research output: Contribution to journal › Article

Paolicelli, D, Cocco, E, Di Lecce, V, Direnzo, V, Moiola, L, Lanzillo, R, Perini, P, Malucchi, S, Borriello, G, Portaccio, E, Panetta, V, Fenu, G, Sangalli, F, Cacciaguerra, L, Trojano, M & for the TRACER Group, TTRACERG 2016, 'Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study', Expert Opinion on Drug Delivery, pp. 1-7. https://doi.org/10.1517/17425247.2016.1158161

Paolicelli, Damiano ; Cocco, Eleonora ; Di Lecce, Valentina ; Direnzo, Vita ; Moiola, Lucia ; Lanzillo, Roberta ; Perini, Paola ; Malucchi, Simona ; Borriello, Giovanna ; Portaccio, Emilio ; Panetta, Valentina ; Fenu, Giuseppe ; Sangalli, Francesca ; Cacciaguerra, Laura ; Trojano, Maria ; for the TRACER Group, the TRACER Group. / Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis : TRACER study. In: Expert Opinion on Drug Delivery. 2016 ; pp. 1-7.

@article{4c2010222e154b2ab2199f8ccd2bc1e3,

title = "Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study",

abstract = "Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart{\textregistered}. This electronic device records the performed injections and assesses adherence as the percentage of {\textquoteleft}not missing doses{\textquoteright}, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined {\textquoteleft}treatment adherents{\textquoteright}. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score ",

keywords = "Disease-modifying drugs, interferon beta, patient adherence, real-life setting, rebismart{\textregistered} injection device, relapsing-remitting multiple sclerosis",

author = "Damiano Paolicelli and Eleonora Cocco and {Di Lecce}, Valentina and Vita Direnzo and Lucia Moiola and Roberta Lanzillo and Paola Perini and Simona Malucchi and Giovanna Borriello and Emilio Portaccio and Valentina Panetta and Giuseppe Fenu and Francesca Sangalli and Laura Cacciaguerra and Maria Trojano and {for the TRACER Group}, {the TRACER Group}",

year = "2016",

month = mar

day = "13",

doi = "10.1517/17425247.2016.1158161",

language = "English",

pages = "1--7",

journal = "Expert Opinion on Drug Delivery",

issn = "1742-5247",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis

T2 - TRACER study

AU - Paolicelli, Damiano

AU - Cocco, Eleonora

AU - Di Lecce, Valentina

AU - Direnzo, Vita

AU - Moiola, Lucia

AU - Lanzillo, Roberta

AU - Perini, Paola

AU - Malucchi, Simona

AU - Borriello, Giovanna

AU - Portaccio, Emilio

AU - Panetta, Valentina

AU - Fenu, Giuseppe

AU - Sangalli, Francesca

AU - Cacciaguerra, Laura

AU - Trojano, Maria

AU - for the TRACER Group, the TRACER Group

PY - 2016/3/13

Y1 - 2016/3/13

N2 - Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of ‘not missing doses’, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined ‘treatment adherents’. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score

AB - Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of ‘not missing doses’, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined ‘treatment adherents’. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score

KW - Disease-modifying drugs

KW - interferon beta

KW - patient adherence

KW - real-life setting

KW - rebismart® injection device

KW - relapsing-remitting multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84961210036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961210036&partnerID=8YFLogxK

U2 - 10.1517/17425247.2016.1158161

DO - 10.1517/17425247.2016.1158161

M3 - Article

AN - SCOPUS:84961210036

SP - 1

EP - 7

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

ER -

Access to Document

10.1517/17425247.2016.1158161